PAT. & TRADEMARK OFF.

1203

A/N #6 4-5 GE

DOCKET NO. 1290-7281

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hervé BOUCHARD et al.

Serial No. : 08/162,984 Batrnh

Filed : December 8, 1993

For : NEW TAXOIDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

TRANSMITTAL LETTER

RECEIVED
DEC 30 1993
APPLICATION DIVISION

HON. COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

1. Enclosed is the original application with Declaration showing original signatures. A facsimile copy of the Declaration was filed in the above-identified patent application on December 8, 1993.

2. Enclosed is a copy of the certified translation of Priority Document No. 92 14813, filed December 9, 1992, which was filed in the above-identified patent application on December 8, 1993.

Respectfully submitted,

MORGAN & FINNEGAN

Date: December 23, 1993

By: Frederick R. Calvetti
Registration No. 28,557

MORGAN & FINNEGAN
555 13th Street, N.W.
Suite 480 West
Washington, D.C. 20004-1109

Tel: (202) 857-7887
Fax: (202) 857-7929

BEST AVAILABLE COPY

142

NIIP

NATIONAL INSTITUTE OF INDUSTRIAL PROPERTY

26bis, rue de Saint-Pétersbourg 75800 Paris Cédex 08 Tel: (1)42 94 52 52 - Telecopier: (1)42 93 59 30

Patents Administrative Division

DESIGNATION OF THE INVENTOR

(if the applicant is not the inventor or the sole inventor)

National Registration No.

92/14,813

Title of the invention: NEW TAXOIDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The undersigned RHONE-POULENC RORER S.A.
20 avenue Raymond Aron
92160 ANTONY

designate(s) as inventor(s) (surname underlined, forenames, address)

Hervé BOUCHARD - 114 avenue Danielle Casanova,
94200 IVRY SUR SEINE

Jean-Dominique BOURZAT - 36 boulevard de la Libération,
94300 VINCENNES

Alain COMMERCON - 1 bis rue Charles Floquet,
94400 VITRY SUR SEINE

NOTE: In exceptional cases, the name of the inventor may be followed by that of the company which he belongs (membership company) when the latter is other than the company which is the applicant or titleholder.

Date and signature(s) of the applicant(s) or of the representative

Antony, 9 December 1992

RHONE-POULENC RORER S.A.
Authorized Representative

(signature)

Jacques PILARD

BA 113/160392

Registration number of the application

92/14,813

INTERNATIONAL PATENT CLASSIFICATION

Int. Cl.: 5

Ignore
these
figures
↓

C 07D 305 /14 ,
H 61K 31 /3(illegible) .

NIIP NATIONAL INSTITUTE OF INDUSTRIAL PROPERTY

Cerfa No. 55-1222

DUPLICATE OF THE APPLICATION

APPLICATION FOR (see ticked box)

a	X	PATENT
b		UTILITY CERTIFICATE
c		DIVISIONAL APPLICATION
d		CONVERSION OF A EUROPEAN PATENT APPLICATION

2 COMPULSORY OPTIONS at the time of filing (except for utility certificate)

THE APPLICANT REQUESTS THE DIFFERED FORMULATION OF THE DOCUMENTATION REPORT: [ ] YES [X] NO

IF THE OPTION SELECTED IS NO AND IF THE APPLICANT IS A PHYSICAL PERSON HE REQUESTS THE GRADUATED PAYMENT OF THE TAX ON THE DOCUMENTATION REPORT: [ ] YES [X] NO

NATURE | NUMBER | DATE OF INITIAL APPLICATION

DATE OF SUBMISSION OF THE DOCUMENTS
09.DEC.1992

for c and d state exactly the nature, number and date of the initial application

3 NAME AND ADDRESS OF THE APPLICANT OR THE REPRESENTATIVE TO WHOM ALL THE CORRESPONDENCE SHOULD BE ADDRESSED

RHONE-POULENC RORER S.A.
Patents Directorate
20 avenue Raymond Aron
92165 ANTONY CEDEX

NATIONAL REGISTRATON No.
92/14.813

DATE OF FILING
09 DEC. 1992

POSTAL CODE OF THE FILING PLACE
75

4 DATE OF THE GENERAL POWER OF ATTORNEY
15 January 1991

5 REFERENCE OF THE CORRESPONDENT
ST 92080

6 TELEPHONE No. OF THE CORRESPONDENT
(1) 40 91 70 29

7 TITLE OF THE INVENTION

NEW TAXOIDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

8 APPLICANT: SURNAME AND CHRISTIAN NAMES (UNDERLINE THE SURNAME) OR NAME AND LEGAL CONSTITUTION

RHONE-POULENC RORER S.A.

SIREN NO. 3 0 4 | 4 6 3 | 2 8 4

9 COMPLETE ADDRESS
20 avenue Raymond Aron
92160 ANTONY

COUNTRY
FRANCE

10 NATIONALITY
French

TAXES PAID

[X] ON FILING

11 INVENTOR(S)
THE APPLICANT IS THE SOLE INVENTOR*
[ ] YES
If the answer is no see explanatory note
[X] NO

12 IF THE APPLICANT IS A PHYSICAL PERSON NOT SUBJECT TO REVENUE COLLECTION, HE REQUESTS OR HAS REQUESTED REDUCTION OF THE TAXES
[ ] YES
[X] NO

[X] ON DOCUMENTATION REPORT

[ ] ON CLAIM TO PRIORITY

[X] ON CLAIM (from the 11th onwards)

13 PRIORITY DECLARATION
COUNTRY OF ORIGIN | FILING DATE | NUMBER

14 [ ] DIVISIONS

PREVIOUS TO THE PRESENT APPLICATION No. | No. | No. | No.

15 SIGNATURE OF THE APPLICANT OR HIS REPRESENTATIVE
NAME AND POSITION OF SIGNATORY
RHONE-POULENC RORER S.A.
Authorized Representative
(signature)
Jacques PILARD

SIGNATURE OF THE RECEIVING OFFICIAL

SIGNATURE OF THE APPLICANT OF THE APPLICATION AT THE N.I.I.P
(illegible signature)

* Tick the relevant box

NEW TAXOIDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to new taxoids of general formula:



their preparation and pharmaceutical compositions containing them.

In general formula (I),

Ar represents an aryl radical,

R represents a hydrogen atom or an acetyl radical,

R_1 represents a benzoyl radical or a radical R_2-O-CO- in which R_2 represents:

- a straight or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl radical containing 2 to 8 carbon atoms, an alkynyl radical containing 3 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a cycloalkenyl radical containing 4 to 6 carbon atoms or a bicycloalkyl radical containing 7 to 11 carbon atoms, these radicals being optionally substituted by one or more substituents chosen from halogen atoms and hydroxy radicals, alkyloxy radicals containing 1 to 4 carbon

atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, piperidino radicals, morpholino radicals, 1-piperazinyl radicals (optionally substituted at position 4 by an alkyl radical containing 1 to 4 carbon atoms or by a phenylalkyl radical whose alkyl portion contains 1 to 4 carbon atoms), cycloalkyl radicals containing 3 to 6 carbon atoms, cycloalkenyl radicals containing 4 to 6 carbon atoms, phenyl radicals, cyano radicals, carboxy radicals or alkyloxycarbonyl radicals whose alkyl portion contains 1 to 4 carbon atoms,

- or a phenyl radical optionally substituted by one or more atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms or alkyloxy radicals containing 1 to 4 carbon atoms,

- or a saturated or unsaturated 4- to 6-membered nitrogen-containing heterocyclyl radical optionally substituted by one or more alkyl radicals containing 1 to 4 carbon atoms,

it being understood that the cycloalkyl, cycloalkenyl or bicycloalkyl radicals may be optionally substituted by one or more alkyl radicals containing 1 to 4 carbon atoms.

Preferably, Ar represents a phenyl or α- or β-naphthyl radical optionally substituted by one or more atoms or radicals chosen from halogen atoms (fluorine, chlorine, bromine, or iodine) and alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxy, alkylthio,

aryloxy, arylthio, hydroxy, hydroxyalkyl, mercapto, formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino, alkylamino, dialkylamino, carboxy, alkoxycarbonyl, carbamoyl, dialkylcarbamoyl, cyano, nitro and trifluoromethyl radicals, it being understood that the alkyl radicals and the alkyl portions of the other radicals contain 1 to 4 carbon atoms, that the alkenyl and alkynyl radicals contain 2 to 8 carbon atoms and that the aryl radicals are phenyl or α- or β-naphthyl radicals or alternatively Ar represents a 5-membered aromatic heterocyclic radical containing one or more atoms, which are identical or different, chosen from nitrogen, oxygen or sulphur atoms, optionally substituted by one or more substituents, which are identical or different, chosen from halogen atoms (fluorine, chlorine, bromine or iodine) and alkyl radicals containing 1 to 4 carbon atoms, aryl radicals containing 6 to 10 carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms, aryloxy radicals containing 6 to 10 carbon atoms, amino radicals, alkylamino radicals containing 1 to 4 carbon atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, acylamino radicals in which the acyl portion contains 1 to 4 carbon atoms, alkoxycarbonylamino radicals containing 1 to 4 carbon atoms, acyl radicals containing 1 to 4 carbon atoms, arylcarbonyl radicals in which the aryl portion contains 6 to 10 carbon atoms, cyano radicals,

carboxy radicals, carbamoyl radicals, alkylcarbamoyl radicals in which the alkyl portion contains 1 to 4 carbon atoms, dialkylcarbamoyl radicals in which each alkyl portion contains 1 to 4 carbon atoms or alkoxycarbonyl radicals in which the alkoxy portion contains 1 to 4 carbon atoms.

More particularly, Ar represents a phenyl, 2- or 3-thienyl or 2- or 3-furyl radical optionally substituted by one or more atoms or radicals, which are identical or different, chosen from halogen atoms and alkyl, alkoxy, amino, alkylamino, dialkylamino, acylamino, alkoxycarbonylamino and trifluoromethyl radicals.

Still more particularly, Ar represents a phenyl radical optionally substituted by a chlorine or fluorine atom or by an alkyl (methyl), alkoxy (methoxy), dialkylamino (dimethylamino), acylamino (acetylamino) or alkoxycarbonylamino (tert-butoxycarbonylamino) or 2- or 3-thienyl or 2- or 3-furyl radical.

Of even more special interest are the products of general formula (I) in which Ar represents a phenyl radical and R represents a benzoyl or tert-butoxycarbonyl radical.

According to the present invention, the new taxoids of general formula (I) can be obtained from a product of general formula:



alkoxy, amino, alkylamino, dialkylamino, acylamino, alkoxycarbonylamino and trifluoromethyl radicals.

Still more particularly, Ar represents a phenyl radical optionally substituted by a chlorine or fluorine atom or by an alkyl (methyl), alkoxy (methoxy), dialkylamino (dimethylamino), acylamino (acetylamino) or alkoxycarbonylamino (tert-butoxycarbonylamino) or 2- or 3-thienyl or 2- or 3-furyl radical.

Of even more special interest are the products of general formula (I) in which Ar represents a phenyl radical and R_1 represents a benzoyl or tert-butoxycarbonyl radical.

According to the present invention, the new taxoids of general formula (I) can be obtained from a product of general formula:



(II)

in which Ar and R_1 are defined as above and R_3 and R_4, which are identical or different represent a hydrogen atom or an alkyl radical containing 1 to 4 carbon atoms, or an aralkyl radical whose alkyl portion contains 1 to 4 carbon atoms and the aryl portion preferably represents a phenyl radical optionally substituted by one or more alkoxy radicals containing 1 to 4 carbon atoms, or an aryl radical preferably representing a phenyl radical optionally substituted by one or more alkoxy radicals containing 1 to 4 carbon atoms, or alternatively R_3 represents an alkoxy radical containing 1 to 4 carbon atoms or a trihalomethyl radical such as trichloromethyl or a phenyl radical substituted by a trihalomethyl radical such as trichloromethyl and R_4 represents a hydrogen atom, or alternatively R_3 and R_4 form, together with the carbon atom to which they are attached, a 4- to 7-membered ring, and G_1 represents a hydroxy-protecting group, the procedure being carried out, according to the meanings of R_3 and R_4, in the following manner:

1) when R_3 represents a hydrogen atom or an alkoxy radical containing 1 to 4 carbon atoms or an



(II)

in which Ar and R_1 are defined as above and R_3 and R_4, which are identical or different represent a hydrogen atom or an alkyl radical containing 1 to 4 carbon atoms, or an aralkyl radical whose alkyl portion contains 1 to 4 carbon atoms and the aryl portion preferably represents a phenyl radical optionally substituted by one or more alkoxy radicals containing 1 to 4 carbon atoms, or an aryl radical preferably representing a phenyl radical optionally substituted by one or more alkoxy radicals containing 1 to 4 carbon atoms, or alternatively R_3 represents an alkoxy radical containing 1 to 4 carbon atoms or a trihalomethyl radical such as trichloromethyl or a phenyl radical substituted by a trihalomethyl radical such as trichloromethyl and R_4 represents a hydrogen atom, or alternatively R_3 and R_4 form, together with the carbon atom to which they are attached, a 4- to 7-membered ring, and G_1 represents a hydrgen atom or an acetyl radical or a hydroxy-protecting group, the procedure being carried out, according to the meanings of R_3 and R_4, in the following manner:

1) when R_3 represents a hydrogen atom or an

optionally substituted aryl radical and R_4 represents a hydrogen atom, the product of general formula (II) is treated in acidic medium in order to obtain a product of general formula:



(III)

in which Ar, R_1 and G_1 are defined as above, whose G_1 radical is, if necessary, replaced by a hydrogen atom.

The deprotection of the side chain of the product of general formula (II) can also be carried out in the presence of an inorganic acid (hydrochloric acid or sulphuric acid) or an organic acid (acetic acid, methanesulphonic acid, trifluoromethanesulphonic acid or p-toluenesulphonic acid), used alone or in the form of a mixture, the procedure being carried out in an organic solvent chosen from alcohols (methanol, ethanol or isopropanol), ethers (tetrahydrofuran, diisopropyl ether or methyl t-butyl ether), esters (ethyl acetate, isopropyl acetate or n-butyl acetate), aliphatic hydrocarbons (pentane, hexane or heptane), halogenated aliphatic hydrocarbons (dichloromethane or 1,2-dichloroethane), aromatic hydrocarbons (benzene, toluene or xylenes) and nitriles (acetonitrile) at a temperature of between -10 and 60°C, preferably between

alkoxy radical containing 1 to 4 carbon atoms or an optionally substituted aryl radical and R_4.



15 and 30°C. The acid may be used in a catalytic or stoichiometric quantity or in excess.

The deprotection can also be carried out under oxidizing conditions, using for example ammonium cerium(IV) nitrate in an acetonitrile-water mixture or 2,3-dichloro-5,6-dicyano-1,4-benzoquinone in water.

The deprotection can also be carried out under reducing conditions, for example by hydrogenolysis in the presence of a catalyst.

When G_1 represents a protecting group, it is preferably a 2,2,2-trichloroethoxycarbonyl or 2-(2-trichloromethylpropoxy)carbonyl radical whose replacement by a hydrogen atom is carried out using zinc, optionally combined with copper, in the presence of acetic acid, at a temperature of between 20 and 60°C or by means of an inorganic or organic acid such as hydrochloric acid or acetic acid in a solution in an aliphatic alcohol containing 1 to 3 carbon atoms or in an aliphatic ester such as ethyl acetate, isopropyl acetate or n-butyl acetate in the presence of zinc optionally combined with copper.

2) when R_3 and R_4, which are identical or different, represent an alkyl radical containing 1 to 4 carbon atoms, or an aralkyl radical whose alkyl portion contains 1 to 4 carbon atoms and the aryl portion is preferably an optionally substituted phenyl radical, or alternatively R_3 represents a trihalomethyl radical or a phenyl radical substituted by a trihalomethyl radical

and R_4 represents a hydrogen atom, or alternatively R_3 and R_4 form, together with the carbon atom to which they are attached, a 4- to 7-membered ring, the product of general formula (II) is converted to the product of general formula:



(IV)

in which Ar and G_1 are defined as above, which is acylated by means of benzoyl chloride or a reactive derivative of general formula:

$$R_2\text{-O-CO-X} \quad \text{(V)}$$

in which R_2 is defined as above and X represents a halogen atom (fluorine or chlorine) or a residue $-O-R_2$ or $-O-CO-O-R_2$, to give a product of general formula (III) in which Ar, R_1 and G_1 are defined as above, whose G_1 radical is, if necessary, replaced by a hydrogen atom.

The products of general formula (IV) can be obtained by treating a product of general formula (II), in which Ar, R_1 and G_1 are defined as above, R_3 and R_4, which are identical or different, represent an alkyl, aralkyl or aryl radical, or alternatively R_3 and R_4 form together with the carbon atom to which they are attached a 4- to 7-membered ring, with an inorganic

acid (hydrochloric acid or sulphuric acid) or an organic acid (formic acid) optionally in an alcohol containing 1 to 3 carbon atoms (methanol, ethanol or isopropanol) at a temperature of between 0 and 50°C. Preferably, formic acid is used at a temperature close to 20°C.

The acylation of the product of general formula (IV) by means of benzoyl chloride or a reactive derivative of general formula (V) is carried out in an inert organic solvent chosen from esters such as ethyl acetate, isopropyl acetate or n-butyl acetate and halogenated aliphatic hydrocarbons such as dichloromethane or 1,2-dichloroethane in the presence of an inorganic base such as sodium bicarbonate or an organic base such as triethylamine. The reaction is carried out at a temperature of between 0 and 50°C, preferably close to 20°C.

When the radical G_1 represents a protecting group, its replacement by a hydrogen atom is carried out under the conditions described above.

The products of general formula (II) can be obtained according to one of the following methods:

1) by esterification of the product of general formula:



(VI)

in which G_1 is defined as above, by means of an acid of general formula:



(VII)

in which Ar, R_1, R_3 and R_4 are defined as above, or of a derivative of this acid.

The esterification by means of an acid of general formula (VII) can be carried out in the presence of a condensing agent (carbodiimide, reactive carbonate) and an activating agent (aminopyridine) in an organic solvent (ether, ester, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons or aromatic hydrocarbons) at a temperature of between -10 and 90°C.

The esterification may also be performed using the acid of general formula (VII) in anhydride form, the procedure being carried out in the presence of an activating agent (aminopyridine) in an organic solvent (ethers, esters, ketones, nitriles, aliphatic

hydrocarbons, halogenated aliphatic hydrocarbons or aromatic hydrocarbons) at a temperature of between 0 and 90°C.

The esterification can also be performed using the acid of general formula (VII) in halide form or in anhydride form with an aliphatic or aromatic acid, optionally prepared in situ, in the presence of a base (tertiary aliphatic amine), the procedure being carried out in an organic solvent (ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons or aromatic hydrocarbons) at a temperature of between 0 and 80°C.

The acid of general formula (VII) can be obtained by saponification of an ester of general formula:



(VIII)

in which Ar, R_1, R_3 and R_4 are defined as above and R_5 represents an alkyl radical containing 1 to 4 carbon atoms optionally substituted by a phenyl radical.

Generally, the saponification is carried out by means of an inorganic base (alkali metal hydroxide, carbonate or bicarbonate) in aqueous-alcoholic medium (methanol-water) at a temperature of between 10 and 40°C.

The ester of general formula (VIII) can be

obtained by the action of a product of general formula:



(IX)

in which R_3 and R_4 are defined as above in the form of a dialkylacetal or an enol alkyl ether, on an ester of general formula:



(X)

in which Ar, R_1 and R_5 are defined as above, the procedure being carried out in an inert organic solvent (aromatic hydrocarbon) in the presence of a strong inorganic acid (sulphuric acid) or organic acid (p-toluenesulphonic acid optionally in the form of a pyridinium salt) at a temperature of between 0°C and the boiling temperature of the reaction mixture.

The ester of general formula (X) can be obtained by the action of a product of general formula (V) on an ester of general formula:



(XI)

in which Ar and R_5 are defined as above, the procedure being carried out in an organic solvent (ester, halogenated aliphatic hydrocarbon) in the presence of

an inorganic or organic base at a temperature of between 0 and 50°C.

The product of general formula (XI) can be obtained by reduction of an azide of general formula:



(XII)

in which Ar and R_5 are defined as above, by means of hydrogen in the presence of a catalyst such as palladium on carbon, the procedure being carried out in an organic solvent (ester).

The product of general formula (XII) can be obtained by the action of an azide such as trimethylsilyl azide in the presence of zinc chloride or an alkali metal (sodium, potassium or lithium) azide in aqueous-organic medium (water-tetrahydrofuran) at a temperature of between 20°C and the boiling temperature of the reaction mixture, on an epoxide of general formula:



(XIII)

in which Ar and R_5 are defined as above, optionally prepared in situ.

The epoxide of general formula (XIII) can be obtained, optionally in situ, by dehydrohalogenation of

a product of general formula:



(XIV)

in which Ar is defined as above, Hal represents a halogen atom, preferably a bromine atom, and R_6 and R_7, which are identical or different, represent a hydrogen atom or an alkyl radical containing 1 to 4 carbon atoms or a phenyl radical, at least one being an alkyl radical or a phenyl radical, by means of an alkali-metal alcoholate, optionally prepared in situ, in an inert organic solvent such as tetrahydrofuran at a temperature of between -80°C and 25°C.

The product of general formula (XIV) can be obtained by the action of an aldehyde of general formula:

Ar-CHO (XV)

in which Ar is defined as above, on a halide of general formula:



(XVI)

in which Hal, R_6 and R_7 are defined as above, anionized beforehand.

Generally, the procedure is carried out in an inert organic solvent chosen from ethers (ethyl ether) and halogenated aliphatic hydrocarbons (methylene chloride) at a temperature of between -80 and 25°C, in the presence of a tertiary amine (triethylamine) and an enolysing agent (di-n-butylboron triflate).

The product of general formula (XVI) can be obtained by the action of a halide of a haloacetic acid, preferably bromoacetic acid bromide, on the corresponding oxazolidinone.

The product of general formula (XI) can be obtained by hydrogenolysis of a product of general formula:



(XVII)

in which Ar and R_5 are defined as above and Ph represents an optionally substituted phenyl radical.

Generally, the hydrogenolysis is carried out by means of hydrogen in the presence of a catalyst. More particularly, palladium on carbon containing 1 to 10 % by weight of palladium or palladium dihydroxide containing 20 % by weight of palladium is used as catalyst.

The hydrogenolysis is carried out in an organic solvent or in a mixture of organic solvents. It

is advantageous to carry out the procedure in acetic acid optionally combined with an aliphatic alcohol containing 1 to 4 carbon atoms such as a mixture of acetic acid-methanol at a temperature of between 20 and 80°C.

The hydrogen necessary for the hydrogenolysis can also be provided by a compound which liberates hydrogen by chemical reaction or by thermal decomposition (ammonium formate). It is advantageous to carry out the procedure at a hydrogen pressure of between 1 and 50 bar.

The product of general formula (XVII) can be obtained by hydrolysis or alcoholysis of a product of general formula:



(XVIII)

in which Ar and Ph are defined as above.

It is particularly advantageous to carry out an alcoholysis by means of an alcohol of formula R_5-OH in which R_5 is defined as above, the procedure being carried out in acidic medium.

Preferably, the alcoholysis is carried out by means of methanol in the presence of a strong inorganic acid such as hydrochloric acid at a temperature close to the reflux temperature of the reaction mixture.

The product of general formula (XVIII) can be obtained by saponification of an ester of general formula:



(XIX)

in which Ar and Ph are defined as above and R_8 represents an alkyl, phenylalkyl or phenyl radical, followed by separation of the 3R,4S diastereoisomer of general formula (XVII) from the other diastereoisomers.

Generally, the saponification is carried out by means of an inorganic or organic base such as ammonium hydroxide, lithium hydroxide, sodium hydroxide or potassium hydroxide in a suitable solvent such as a methanol-water or tetrahydrofuran-water mixture at a temperature of between -10°C and 20°C.

The separation of the 3R,4S diastereoisomer can be carried out by selective crystallization from a suitable organic solvent such as ethyl acetate.

The product of general formula (XIX) can be obtained by cycloaddition of an imine of general formula:



(XX)

in which Ar and Ph are defined as above, onto an acid halide of general formula:



(XXI)

in which R_8 is defined as above and Y represents a halogen atom such as a bromine or chlorine atom.

Generally, the reaction is carried out at a temperature of between 0 and 50°C in the presence of a base chosen from aliphatic tertiary amines (triethylamine) or pyridine in an organic solvent chosen from optionally halogenated aliphatic hydrocarbons (methylene chloride or chloroform) and aromatic hydrocarbons (benzene, toluene or xylenes).

The product of general formula (XX) can be obtained under conditions analogous to those described by M. Furukawa et al., Chem. Pharm. Bull., 25 (1), 181-184 (1977).

The product of general formula (VI) can be obtained by the action of an alkali metal halide (sodium iodide or potassium fluoride) or an alkali metal azide (sodium azide) on a baccatin III or 10-deacetylbaccatin III derivative of general formula:



(XXII)

in which G_1 is defined as above.

Generally, the reaction is carried out in an organic solvent chosen from ethers (tetrahydrofuran, diisopropyl ether, methyl t-butyl ether) and nitriles (acetonitrile), alone or in the form of a mixture, at a temperature of between 20°C and the boiling temperature of the reaction mixture.

The baccatin III or 10 deacetylbaccatin III derivative of formula (XXII) can be obtained by the action of a trifluoromethanesulphonic acid derivative such as the anhydride or N-phenyltrifluoromethanesulphonimide, on baccatin III or 10-deacetylbaccatin III, which can be extracted according to known methods from yew leaves (Taxus baccata), optionally followed by protection in position 10..

Generally, the reaction is carried out in an inert organic solvent (optionally halogenated aliphatic hydrocarbons, or aromatic hydrocarbons) in the presence of an organic base such as an aliphatic tertiary amine (triethylamine) or pyridine, at a temperature of between -50 and +20°C.

2) by the action of an alkali metal halide (sodium

iodide or potassium fluoride) or an alkali metal azide (sodium azide) on a product of general formula:



(XXIII)

in which Ar, R_1, R_3, R_4 and G_1 are defined as above.

Generally, the reaction is carried out in an organic solvent chosen from ethers (tetrahydrofuran, diisopropyl ether or methyl t-butyl ether) and nitriles (acetonitrile), alone or in the form of a mixture, at a temperature of between 20°C and the boiling temperature of the reaction mixture.

The product of general formula (XXIII) can be obtained by the action of a trifluoromethanesulphonic acid derivative such as the anhydride or N-phenyltrifluoromethanesulphonimide on a taxoid of general formula:



(XXIV)

in which Ar, R_1, R_3, R_4 and G_1 are defined as above.

Generally, the reaction is carried out in an

inert organic solvent (optionally halogenated aliphatic hydrocarbons, or aromatic hydrocarbons) in the presence of an organic base such as an aliphatic tertiary amine (triethylamine) or pyridine, at a temperature of between -50 and +20°C.

The taxoid of general formula (XXIV), in which G_1 represents a hydrogen atom or an acetyl radical, can be obtained from a product of general formula:



(XXV)

in which Ar, R_1, R_3 and R_4 are defined as above, G'_1 represents a hydroxy-protecting group and G'_2 represents an acetyl radical or a hydroxy-protecting group, by replacement of the protecting groups G_1 and optionally G_2 by hydrogen atoms.

The radicals G'_1 and G'_2, when they represent a hydroxy-protecting group, are preferably 2,2,2-trichloroethoxycarbonyl or 2-(2-trichloromethylpropoxy)carbonyl radicals or trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl or triarylsilyl radicals in which the alkyl portions contain 1 to 4 carbon atoms and the aryl portions are preferably phenyl radicals.

When G'_1 and G'_2 represent a 2,2,2-trichloroethoxycarbonyl or 2-(2-trichloromethylpropoxy)carbonyl radical, the replacement of the protecting groups by hydrogen atoms is carried out using zinc, optionally combined with copper, in the presence of acetic acid at a temperature of between 20 and 60°C or by means of an inorganic or organic acid such as hydrochloric acid or acetic acid in solution in an aliphatic alcohol containing 1 to 3 carbon atoms or an aliphatic ester such as ethyl acetate, isopropyl acetate or n-butyl acetate in the presence of zinc optionally combined with copper.

When G'_1 represents a silylated radical and G'_2 represents an acetyl radical, the replacement of the protecting group by a hydrogen atom can be carried out by means of, for example, gaseous hydrochloric acid in ethanolic solution at a temperature close to 0°C, under conditions which are without effect on the rest of the molecule.

The product of general formula (XXV) can be obtained under the conditions described in international application PCT/WO 9209589.

The new derivatives of general formula (I) can also be obtained by esterification of a product of general formula (VI) by means of an acid of general formula:



(XXVI)

in which Ar and R_1 are defined as above and G_3 represents a hydroxy-protecting group chosen from methoxymethyl, 1-ethoxyethyl, benzyloxymethyl, (β-trimethylsilyloxy)methyl, tetrahydropyranyl, 2,2,2-trichloroethoxymethyl, 2,2,2-trichloroethoxycarbonyl or 2-(2-trichloromethylpropoxy)carbonyl radicals or CH_2-Ph radicals in which Ph represents a phenyl radical optionally substituted by one or more atoms or radicals, which are identical or different, chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atoms, or an activated derivative of this acid, to give a product of general formula:



(XXVII)

in which Ar, R_1, G_1 and G_3 are defined as above, followed by the replacement of the protecting groups G_1 and G_3 by hydrogen atoms to give a product of general formula (I).

The esterification can be performed under the

conditions described above for the esterification of the product of general formula (VI) by means of an acid of general formula (VII).

The replacement of the protecting groups G_1 and G_3 of the product of general formula (XXVII) by a hydrogen atom is carried out by treatment with zinc, optionally combined with copper, in the presence of acetic acid at a temperature of between 30 and 60°C or by means of an inorganic or organic acid such as hydrochloric acid or acetic acid in solution in an aliphatic alcohol containing 1 to 3 carbon atoms or an aliphatic ester such as ethyl acetate, isopropyl acetate or n-butyl acetate in the presence of zinc optionally combined with copper, when G_1 and G_3 represent a 2,2,2-trichloroethoxycarbonyl or 2-(2-trichloromethylpropoxy)carbonyl radical. The replacement of the protecting group G_3, when it represents a silylated radical, can be carried out by treatment in acidic medium such as for example hydrochloric acid in solution in an aliphatic alcohol containing 1 to 3 carbon atoms (methanol, ethanol, propanol or isopropanol) or aqueous hydrofluoric acid at a temperature of between 0 and 40°C, when it represents an acetal residue, the replacement of the protecting group G_1 then being carried out under the conditions described above. When G_3 represents a group $-CH_2-Ph$, the replacement of this protecting group with a hydrogen atom can be carried out by hydrogenolysis in



in which Ar and R_1 are defined as above and G_3 represents a hydroxy-protecting group chosen from methoxymethyl, 1-ethoxyethyl, benzyloxymethyl, (β-trimethylsilyloxy)methyl, tetrahydropyranyl, 2,2,2-trichloroethoxymethyl, 2,2,2-trichloroethoxycarbonyl or 2-(2-trichloromethylpropoxy)carbonyl radicals or CH_2-Ph radicals in which Ph represents a phenyl radical optionally substituted by one or more atoms or radicals, which are identical or different, chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atoms, or an activated derivative of this acid, to give a product of general formula:

the presence of a catalyst.

The acid of general formula (XXVI) can be obtained by saponification of an ester of general formula:



(XXVIII)

in which Ar, R_1, R_5 and G_3 are defined as above.

Generally, the saponification is carried out by means of an inorganic base (alkali metal hydroxide, carbonate or bicarbonate) in aqueous-alcoholic medium (methanol-water) at a temperature of between 10 and 40°C.

The ester of general formula (XXVIII) can be obtained according to the usual methods for the preparation of ethers, and more particularly according to the procedures described by J-N. DENIS et al., J. Org. Chem., 51, 46-50 (1986), from a product of general formula (XI).

The new products of general formula (I) obtained using the procedures according to the invention can be purified according to known methods such as crystallization or chromatography.

The products of general formula (I) have remarkable biological properties.

In vitro, measurement of the biological activity is carried out on tubulin extracted from pig brain by the method of M.L. Shelanski et al., Proc.



(XXVII)

in which Ar, R_1, G_1 and G_3 are defined as above, followed by the replacement of the protecting groups G_1 and G_3 by hydrogen atoms to give a product of general formula (I).

The esterification can be performed under the conditions described above for the esterification of the product of general formula (VI) by means of an acid of general formula (VII).

The replacement of the protecting groups G_1 and G_3 of the product of general formula (XXVII) by a hydrogen atom is carried out by treatment with zinc, optionally combined with copper, in the presence of acetic acid at a temperature of between 30 and 60°C or by means of an inorganic or organic acid such as hydrochloric acid or acetic acid in solution in an aliphatic alcohol containing 1 to 3 carbon atoms or an aliphatic ester such as ethyl acetate, isopropyl acetate or n-butyl acetate in the presence of zinc optionally combined with copper, when G_1 and G_3 represent a 2,2,2-trichloroethoxycarbonyl or 2-(2-trichloromethylpropoxy)carbonyl radical. The replacement of the protecting group G_3, when it

Natl. Acad. Sci. USA, 70, 765-768 (1973). The study of the depolymerization of the microtubules into tubulin is carried out according to the method of G. Chauvière et al., C.R. Acad. Sci., 293, series II, 501-503 (1981). In this study, the products of general formula (I) proved at least as active as taxol and Taxotere.

In vivo, the products of general formula (I) proved active in mice grafted with the B16 melanoma at doses of between 1 and 10 mg/kg intraperitoneally, as well as on other liquid or solid tumours.

The following example illustrates the present invention.

EXAMPLE

A solution of 2.01 g of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,10β-dihydroxy-7β,8β-methylene-9-oxo-19-nor-11-taxen-13α-yl (4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate in 20 cm^3 of formic acid is stirred for 4 hours at a temperature close to 20°C and then concentrated to dryness under reduced pressure (0.27 kPa) at 40°C. The foam obtained is dissolved in 100 cm^3 of dichloromethane and the solution obtained is supplemented with 20 cm^3 of a saturated aqueous sodium hydrogen carbonate solution. The aqueous phase is separated after settling has taken place and extracted with 20 cm^3 of dichloromethane. The organic phases are pooled, dried over magnesium sulphate, filtered and

represents a silylated radical or an acetal residue, can be carried out by treatment in acidic medium such as for example hydrochloric acid in solution in



then concentrated to dryness under reduced pressure (2.7 kPa) at 40°C. 1.95 g of a white foam are obtained which are purified by chromatography on 200 g of silica (0.063-0.2 mm) contained in a column 7 cm in diameter, eluting with a dichloromethane-methanol mixture (98-2 by volume) and collecting 30 cm^3 fractions. The fractions containing only the desired product are pooled and concentrated to dryness under reduced pressure (0.27 kPa) at 40°C for 2 hours. 1.57 g of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,10β-dihydroxy-7β,8β-methylene-9-oxo-19-nor-11-taxen-13α-yl (2R,3S)-3-amino-2-hydroxy-3-phenylpropionate are obtained in the form of a white foam.

To a solution of 400 mg of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,10β-dihydroxy-7β,8β-methylene-9-oxo-19-nor-11-taxen-13α-yl (2R,3S)-3-amino-2-hydroxy-3-phenylpropionate in 1 cm^3 of dichloromethane, kept under an argon atmosphere, are added 60 mg of sodium hydrogen carbonate and then, dropwise, at a temperature close to 20°C, a solution of 0.16 g of di-tert-butyl dicarbonate in 1 cm^3 of dichloromethane. The solution obtained is stirred for 64 hours at a temperature close to 20°C and then supplemented with a mixture of 5 cm^3 of distilled water and 10 cm^3 of dichloromethane. The organic phase is washed with three times 2 cm^3 of distilled water. The organic phase is dried over magnesium sulphate, filtered and then concentrated to dryness under reduced

pressure (2.7 kPa) at 40°C. 317 mg of a white foam are thus obtained which are purified by chromatography on 30 g of silica (0.063-0.2 mm) contained in a column 3 cm in diameter, eluting with a dichloromethane-methanol mixture (95-5 by volume) and collecting 5 cm^3 fractions. The fractions containing only the desired product are pooled and concentrated to dryness under reduced pressure (0.27 kPa) at 40°C for 2 hours. 161 mg of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,10β-dihydroxy-7β,8β-methylene-9-oxo-19-nor-11-taxen-13α-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate are thus obtained in the form of a white foam whose characteristics are the following:

- specific rotation: $[\alpha]_D^{20}$ = -17° (c = 0.482; methanol)
- NMR spectrum: (400 MHz; $CDCl_3$; temperature of 323 K; δ in ppm; coupling constants J in Hz):1.21 (s, 3H:-C<u>H</u>$_3$ 16 or 17); 1.28 (s, 3H:-C<u>H</u>$_3$ 16 or 17); 1.34 [s, 9H:-C(C<u>H</u>$_3$)$_3$]; from 1.30 to 1.50 (mt, 1H:-<u>H</u>7); 1.80 and 2.36 (2mt, 1H each:-C<u>H</u>$_2$- of cyclopropane); 1.88 (s, 3H:-C<u>H</u>$_3$ 18); 2.13 [mt, 1H:-(CH)-<u>H</u> 6]; 2.26 [dd, 1H, J = 15 and 8.5:-(CH)-<u>H</u> 14]; 2.35 (s, 3H:-COC<u>H</u>$_3$); from 2.35 to 2.50 [mt, 2H:-(CH) -<u>H</u> 14 and -(CH)-<u>H</u> 6]; 3.21 (d, 1H, J = 4:-O<u>H</u> 2'); 4.08 [d, 1H, J = 8:-(CH)-<u>H</u> 20]; 4.16 (d, 1H, J = 7: -<u>H</u> 3); 4.18 (s, 1H, -O<u>H</u> 10); 4.31 [d, 1H, J = 8:-(CH)-<u>H</u> 20]:4.61 (dd, 1H, J = 4 and 2:-<u>H</u> 2'); 4.74 (d, 1H, J = 4:-<u>H</u> 5); 5.00 (s, 1H:-<u>H</u> 10); 5.26 (dd, 1H, J = 9 and 2:-<u>H</u> 3'); 5.33 (d, 1H, J = 9:-N<u>H</u> 3'); 5.69 (d, 1H, J = 7:-<u>H</u> 2); 6.29 (d, 1H, J = 8.5:-<u>H</u> 13); from

7.30 to 7.50 [mt, 5H:-C_6H_5 in 3' (-H 2 to -H 6)]; 7.51 [t, 2H, J = 7.5:-$OCOC_6H_5$ (-H 3 and H 5)]; 7.60 [t, 1H, J = 7.5:-$OCOC_6H_5$ (-H 4)]; 8.14 [d, 2H, J = 7.5: -$OCOC_6H_5$ (-H 2 and H 6)].

The 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,10β-dihydroxy-7β,8β-methylene-9-oxo-19-nor-11-taxen-13α-yl (4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate can be prepared in the following manner:

To a solution of 2.5 g of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,10β-dihydroxy-9-oxo-7β-trifluoromethanesulphonate-11-taxen-13α-yl (4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate in 25 cm^3 of anhydrous acetonitrile and 3 cm^3 of anhydrous tetrahydrofuran, kept under an argon atmosphere, are added 2.5 g of sodium azide. The reaction mixture is heated for 2 hours, with stirring and under an argon atmosphere at a temperature close to 80°C, then cooled to a temperature close to 20°C and supplemented with 30 cm^3 of distilled water. The aqueous phase is separated by decantation and then extracted with 20 cm^3 of dichloromethane. The combined organic phases are dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) at 40°C. 2.44 g of a yellow foam are thus obtained which are purified by chromatography on 300 g of silica (0.063-0.2 mm) contained in a column 8 cm in diameter,

eluting with a dichloromethane-ethyl acetate mixture (90-10 by volume) and collecting 60 cm^3 fractions. Fractions 47 to 70 are pooled and concentrated to dryness under reduced pressure (0.27 kPa) at 40°C for 2 hours. 2.01 g of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,10β-dihydroxy-7β,8β-methylene-9-oxo-19-nor-11-taxen-13α-yl (4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate are thus obtained in the form of a white foam.

The 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,10β-dihydroxy-9-oxo-7β-trifluoromethanesulphonate-11-taxen-13α-yl (4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate can be prepared in the following manner:

To a solution of 2.86 g of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,7β,10β-trihydroxy-9-oxo-11-taxen-13α-yl (4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate in 29 cm^3 of anhydrous dichloromethane, kept under an argon atmosphere, are added 0.955 cm^3 of pyridine and 50 mg of powdered activated 4Å molecular sieve. The reaction mixture is cooled to a temperature close to -35°C, slowly supplemented with 0.85 cm^3 of trifluoromethanesulphonic anhydride, stirred at a temperature close to -5°C for 15 minutes and supplemented with 10 cm^3 of distilled water. After filtration on sintered glass provided with celite and rinsing off the sintered glass with 3 times 10 cm^3 of a

methanol-dichloromethane mixture (10-90 by volume), the aqueous phase is separated after settling has taken place and extracted with twice 10 cm^3 of dichloromethane. The organic phases are pooled, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) at 40°C. 3.87 g of a white foam are obtained which are purified by chromatography on 400 g of silica (0.063-0.2 mm) contained in a column 10 cm in diameter, eluting with a dichloromethane-ethyl acetate gradient (from 97.5-2.5 to 90-10 by volume) and collecting 80 cm^3 fractions. The fractions containing only the desired product are pooled and concentrated to dryness under reduced pressure (0.27 kPa) at 40°C for 2 hours. 3.0 g of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,10β-dihydroxy-9-oxo-7β-trifluoromethanesulphonate-11-taxen-13α-yl (4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate are thus obtained in the form of a white foam.

The 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,7β,10β-trihydroxy-9-oxo-11-taxen-13α-yl (4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate can be prepared in the following manner:

A solution of 24.35 g of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-9-oxo-7β,10β-[bis(2,2,2-trichloroethoxy)carbonyloxy]-1β-hydroxy-11-taxen-13α-yl (4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-

oxazolidinecarboxylate in a mixture of 130 cm^3 of ethyl acetate and 46.5 cm^3 of acetic acid is heated, with stirring and under an argon atmosphere up to a temperature close to 60°C and then supplemented with 40 g of zinc powder. The reaction mixture is then stirred for 30 minutes at 60°C and then cooled to a temperature close to 20°C and filtered on sintered glass provided with celite. The sintered glass is washed with 100 cm^3 of a methanol-dichloromethane mixture (20-80 by volume); the filtrates are pooled and then concentrated to dryness under reduced pressure (0.27 kPa) at a temperature close to 40°C.

The residue is supplemented with 500 cm^3 of dichloromethane. The organic phase is washed with twice 50 cm^3 of a saturated aqueous sodium hydrogen carbonate solution and then with 50 cm^3 of distilled water. The aqueous phases obtained after settling has taken place and pooled are extracted with twice 30 cm^3 of dichloromethane. The organic phases are pooled, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) at 40°C. 19.7 g of a white foam are obtained which are purified by chromatography on 800 g of silica (0.063-0.2 mm) contained in a column 10 cm in diameter, eluting with a dichloromethane-methanol gradient (from 100-0 to 97-3 by volume) and collecting 80 cm^3 fractions. The fractions containing only the desired product are pooled and concentrated to dryness under reduced

pressure (0.27 kPa) at 40°C for 2 hours. 16.53 g of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,7β,10β-trihydroxy-9-oxo-11-taxen-13α-yl (4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate in the form of a white foam.

The 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-9-oxo-7β,10β-[bis(2,2,2-trichloroethoxy)carbonyloxy]-1β-hydroxy-11-taxen-13α-yl (4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate can be prepared according to the method described in international application PCT WO 9209589.

The new products of general formula (I) manifest a significant inhibitory activity with respect to abnormal cell proliferation and possess therapeutic properties which permit the treatment of patients having pathological conditions associated with abnormal cell proliferation. The pathological conditions include the abnormal cell proliferation of malignant or nonmalignant cells of various tissues and/or organs, comprising, with no limitation being implied, muscle, bone or connective tissues, the skin, brain, lungs, sex organs, the lymphatic or renal systems, mammary or blood cells, liver, the digestive tract, pancreas and thyroid or adrenal glands. These pathological conditions can also include psoriasis, solid tumours, cancers of the ovary, breast, brain, prostate, colon, stomach, kidney or testicles, Kaposi's sarcoma, cholangioma, chorioma, neuroblastoma, Wilms' tumour,

Hodgkin's disease, melanomas, multiple myelomas, lymphatic leukaemias and acute or chronic granulocytic lymphomas. The new products according to the invention are particularly useful for the treatment of cancer of the ovary. The products according to the invention can be used to prevent or retard the appearance or reappearance of the pathological conditions or to treat these pathological conditions.

The products according to the invention can be administered to a patient in various forms adapted to the chosen route of administration which is preferably the parenteral route. Parenteral administration comprises intravenous, intraperitoneal, intramuscular or subcutaneous administrations. Intraperitoneal or intravenous administration is more particularly preferred.

The present invention also comprises pharmaceutical compositions containing at least one product of general formula (I) in a sufficient quantity adapted to use in human or veterinary therapy. The compositions can be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants, carriers or excipients. Suitable carriers include diluents, sterile aqueous media and various nontoxic solvents. Preferably, the compositions are provided in the form of aqueous solutions or suspensions, of injectable solutions which may contain emusifying agents, colorants, preservatives or

stabilizers.

The choice of adjuvants or excipients may be determined by the solubility and the chemical properties of the product, the particular mode of administration and good pharmaceutical practice.

For parenteral administration, aqueous or nonaqueous sterile solutions or suspensions are used. For the preparation of nonaqueous solutions or suspensions, natural vegetable oils such as olive oil, sesame oil or paraffin oil or injectable organic esters such as ethyl oleate can be used. The aqueous sterile solutions may consist of a solution of a pharmaceutically acceptable salt in solution in water. The aqueous solutions are suitable for intravenous administration in so far as the pH is appropriately adjusted and isotonicity is achieved, for example, with a sufficient quantity of sodium chloride or glucose. The sterelization can be performed by heating or by any other means which does not adversely affect the composition.

It is clearly understood that all the products entering into the compositions according to the invention should be pure and nontoxic for the quantities used.

The compositions may contain at least 0.01 % of therapeutically active product. The quantity of active product in a composition is such that a suitable dosage can be prescribed. Preferably, the compositions

are prepared such that a single dose contains about 0.01 to 1000 mg of active product for parenteral administration.

The therapeutic treatment can be performed concurrently with other therapeutic treatments including antineoplastic drugs, monoclonal antibodies, immunotherapies or radiotherapies or biological response modifiers. The response modifiers include, with no limitation being implied, lymphokines and cytokines such as interleukins, interferons (α, β or δ) and TNF. Other chemotherapeutic agents which are useful in the treatment of disorders caused by abnormal proliferation of cells include, with no limitation being implied, alkylating agents like nitrogen mustards such as mechloretamine, cyclophosphamide, melphalan and chlorambucil, alkyl sulphonates such as busulfan, nitrosoureas such as carmustine, lomustine, semustine and streptozocin, triazenes such as dacarbazine, antimetabolites such as folic acid analogues like methotrexate, pyrimidine analogues such as fluorouracil and cytarabine, purine analogues such as mercaptopurine and thioguanine, natural products like vinca alkaloids such as vinblastine, vincristine and vendesine, epipodophyllotoxins such as etoposide and teniposide, antibiotics such as dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin and mitomycin, enzymes such as L-asparaginase, various agents such as coordination complexes of platinum like cisplatin,

are prepared such that a single dose contains about 0.01 to 1000 mg of active product for parenteral administration.

The therapeutic treatment can be performed concurrently with other therapeutic treatments including antineoplastic drugs, monoclonal antibodies, immunotherapies or radiotherapies or biological response modifiers. The response modifiers include, with no limitation being implied, lymphokines and cytokines such as interleukins, interferons (α, β or δ) and TNF. Other chemotherapeutic agents which are useful in the treatment of disorders caused by abnormal proliferation of cells include, with no limitation being implied, alkylating agents like nitrogen mustards such as mechloretamine, cyclophosphamide, melphalan and chlorambucil, alkyl sulphonates such as busulfan, nitrosoureas such as carmustine, lomustine, semustine and streptozocin, triazenes such as dacarbazine, antimetabolites such as folic acid analogues like methotrexate, pyrimidine analogues such as fluorouracil and cytarabine, purine analogues such as mercaptopurine and thioguanine, natural products like vinca alkaloids such as vinblastine, vincristine and vendesine, epipodophyllotoxins such as etoposide and teniposide, antibiotics such as dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin and mitomycin, enzymes such as L-asparaginase, various agents such as coordination complexes of platinum like cisplatin,

substituted ureas like hydroxyurea, methylhydrazine derivatives such as procarbazine, adrenocotical suppressants such as mitotane and aminoglutethymide, hormones and antagonists such as adrenocorticosteroids such as prednisone, progestins such as hydroxyprogesterone caproate, methoxyprogesterone acetate and megestrol acetate, oestrogens such as diethylstilbestrol and ethynylestradiol, antioestrogen such as tamoxifen, and androgens such as testosterone propionate and fluoxymesterone.

The doses used for carrying out the methods according to the invention are those which permit a prophylactic treatment or a maximum therapeutic response. The doses vary according to the form of administration, the particular product selected and the characteristics specific to the subject to be treated. In general, the doses are those which are therapeutically effective for the treatment of disorders caused by abnormal cell proliferation. The products according to the invention can be administered as often as necessary to obtain the desired therapeutic effect. Some patients may respond rapidly to relatively high or low doses, and then require low or zero maintenance doses. Generally, low doses will be used at the beginning of the treatment and, if necessary, increasingly higher doses will be administered until an optimum effect is obtained. For other patients, it may be necessary to administer maintenance doses 1 to 8

times per day, preferably 1 to 4 times according to the physiological needs of the patient considered. It is also possible that for certain patients it may be necessary to use only one to two daily administrations.

In man, the doses are generally between 0.01 and 200 mg/kg. For intraperitoneal administration, the doses will generally be between 0.1 and 100 mg/kg and, preferably, between 0.5 and 50 mg/kg and, still more specifically, between 1 and 10 mg/kg. For intravenous administration, the doses are generally between 0.1 and 50 mg/kg and, preferably, between 0.1 and 5 mg/kg and, still more specifically, between 1 and 2 mg/kg. It is understood that, in order to choose the most appropriate dosage, account should be taken of the route of administration, the patient's weight, his general state of health, his age and all factors which may influence the efficacy of the treatment.

The following example illustrates a composition according to the invention.

EXAMPLE

40 mg of the product obtained in Example 1 are dissolved in 1 cm^3 of Emulphor EL 620 and 1 cm^3 of ethanol and then the solution is diluted by addition of 18 cm^3 of physiological saline.

The composition is administered by perfusion for 1 hour by introduction into physiological saline.

CLAIMS

1. New taxoids of general formula:



in which

R represents a hydrogen atom or an acetyl radical,

R_1 represents a benzoyl radical or a radical R_2-O-CO- in which R_2 represents an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, phenyl or heterocyclyl radical, and

Ar represents an aryl radical.

2. New derivatives according to claim 1 for which:

R represents a hydrogen atom or an acetyl radical,

R_1 represents a benzoyl radical or a radical R_2-O-CO in which R_2 represents:

- a straight or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl radical containing 2 to 8 carbon atoms, an alkynyl radical containing 3 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a cycloalkenyl radical containing 4 to 6 carbon atoms or a bicycloalkyl radical containing 7 to 10 carbon atoms, these radicals being optionally substituted by one or more

CLAIMS

1. New taxoids of general formula:



in which

R represents a hydrogen atom or an acetyl radical,

R_1 represents a benzoyl radical or a radical R_2-O-CO- in which R_2 represents an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, phenyl or heterocyclyl radical, and

Ar represents an aryl radical.

2. New derivatives according to claim 1 for which:

R represents a hydrogen atom or an acetyl radical,

R_1 represents a benzoyl radical or a radical R_2-O-CO in which R_2 represents:

- a straight or branched alkyl radical containing 1 to 8 carbon atoms, an alkenyl radical containing 2 to 8 carbon atoms, an alkynyl radical containing 3 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a cycloalkenyl radical containing 4 to 6 carbon atoms or a bicycloalkyl radical containing 7 to 10 carbon atoms, these radicals being optionally substituted by one or more

substituents, which are identical or different, chosen from halogen atoms and hydroxy radicals, alkoxy radicals containing 1 to 4 carbon atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, piperidino radicals, morpholino radicals, 1-piperazinyl radicals (optionally substituted at position 4 by an alkyl radical containing 1 to 4 carbon atoms or by a phenylalkyl radical whose alkyl portion contains 1 to 4 carbon atoms), cycloalkyl radicals containing 3 to 6 carbon atoms, cycloalkenyl radicals containing 4 to 6 carbon atoms, phenyl radicals, cyano radicals, nitroradicals, carboxy radicals or alkoxycarbonyl radicals whose alkyl portion contains 1 to 4 carbon atoms,

- or a phenyl radical optionally substituted by one or more radicals, which are identical or different, chosen from alkyl radicals containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atoms,

- or a saturated or unsaturated 5- or 6-membered nitrogen-containing heterocyclyl radical optionally substituted by one or more alkyl radicals containing 1 to 4 carbon atoms,

it being understood that the cycloalkyl, cycloalkenyl or bicycloalkyl radicals may be optionally substituted by one or more alkyl radicals containing 1 to 4 carbon atoms, and

Ar represents a phenyl or α- or β-naphthyl

substituents, which are identical or different, chosen from halogen atoms and hydroxy radicals, alkoxy radicals containing 1 to 4 carbon atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, piperidino radicals, morpholino radicals, 1-piperazinyl radicals (optionally substituted at position 4 by an alkyl radical containing 1 to 4 carbon atoms or by a phenylalkyl radical whose alkyl portion contains 1 to 4 carbon atoms), cycloalkyl radicals containing 3 to 6 carbon atoms, cycloalkenyl radicals containing 4 to 6 carbon atoms, phenyl radicals, cyano radicals, carboxy radicals or alkoxycarbonyl radicals whose alkyl portion contains 1 to 4 carbon atoms,



radical optionally substituted by one or more atoms or radicals, chosen from halogen atoms (fluorine, chlorine, bromine, or iodine) and alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxy, hydroxyalkyl, mercapto, formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino, alkylamino, dialkylamino, carboxy, alkoxycarbonyl, carbamoyl, dialkylcarbamoyl, cyano, nitro and trifluoromethyl radicals, it being understood that the alkyl radicals and the alkyl portions of the other radicals contain 1 to 4 carbon atoms, that the alkenyl and alkynyl radicals contain 2 to 8 carbon atoms and that the aryl radicals are phenyl or α- or β-naphthyl radicals or alternatively Ar represents a 5-membered aromatic heterocyclic radical containing one or more atoms, which are identical or different, chosen from nitrogen, oxygen or sulphur atoms, optionally substituted by one or more substituents, which are identical or different, chosen from halogen atoms (fluorine, chlorine, bromine or iodine) and alkyl radicals containing 1 to 4 carbon atoms, aryl radicals containing 6 to 10 carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms, aryloxy radicals containing 6 to 10 carbon atoms, amino radicals, alkylamino radicals containing 1 to 4 carbon atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, acylamino radicals in which the acyl portion contains 1 to 4 carbon atoms,

radical R_2-O-CO- in which R_2 represents a t-butyl radical and Ar represents a phenyl radical.

4. Process for the preparation of a product according to one of claims 1, 2 or 3, characterized in that a product of general formula:



in which G_1 represents a hydrogen atom or an acetyl radical or a hydroxy-protecting group, is esterified by means of an acid of general formula:

alkoxycarbonylamino radicals containing 1 to 4 carbon atoms, acyl radicals containing 1 to 4 carbon atoms, arylcarbonyl radicals in which the aryl portion contains 6 to 10 carbon atoms, cyano radicals, carboxy radicals, carbamoyl radicals, alkylcarbamoyl radicals in which the alkyl portion contains 1 to 4 carbon atoms, dialkylcarbamoyl radicals in which each alkyl portion contains 1 to 4 carbon atoms or alkoxycarbonyl radicals in which the alkoxy portion contains 1 to 4 carbon atoms.

3. New derivatives according to claim 1, for which R represents a hydrogen atom or an acetyl radical, R_1 represents a benzoyl radical or a radical R_2-O-CO- in which R_2 represents a t-butyl radical and Ar represents a phenyl radical.

4. Process for the preparation of a product according to one of claims 1, 2 or 3, characterized in that a product of general formula:



in which G_1 represents a hydrogen atom or an acetyl radical or a hydroxy-protecting group, is esterified by means of an acid of general formula:



in which Ar and R_1 are defined as in one of claims 1, 2 or 3, R_3 represents a hydrogen atom or an alkoxy radical containing 1 to 4 carbon atoms or an optionally substituted aryl radical and R_4 represents a hydrogen atom, to give a product of general formula:



in which Ar, R and R_1 are defined as in one of claims 1, 2 or 3, R_3, R_4 and G_1 are defined as above, which is treated in acidic medium to give a product of general formula:



in which Ar, R_1 and G_1 are defined as above, and then the protecting group G_1 is optionally replaced by a hydrogen atom and the product obtained is isolated.



in which Ar and R_1 are defined as in one of claims 1, 2 or 3, R_3 represents a hydrogen atom or an alkoxy radical or an optionally substituted aryl radical and R_4 represents a hydrogen atom, to give a product of general formula:



in which Ar, R and R_1 are defined as in one of claims 1, 2 or 3, R_3, R_4 and G_1 are defined as above, which is treated in acidic medium to give a product of general formula:



(I)

5. Process according to claim 4, characterized in that the esterification is carried out by means of the free acid, the procedure being carried out in the presence of a condensing agent chosen from carbodiimides and reactive carbonates and an activating agent chosen from aminopyridines in an organic solvent chosen from ethers, ketones, esters, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between -10 and 90°C.

6. Process according to claim 4, characterized in that the esterification by means of the anhydride is carried out in the presence of an activating agent chosen from aminopyridines in an organic solvent chosen from ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between 0 and 90°C.

7. Process according to claim 4, characterized in that the esterification is carried out by means of a halide or an anhydride with an aliphatic or aromatic acid, optionally prepared in situ, the procedure being carried out in the presence of a base chosen from tertiary aliphatic amines in an organic solvent chosen from ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between 0 and 80°C.

in which Ar, R_1 and G_1 are defined as above, and then the protecting group G_1 is optionally replaced by a hydrogen atom and the product obtained is isolated.

5. Process according to claim 4, characterized in that the esterification is carried out by means of the free acid, the procedure being carried out in the presence of a condensing agent chosen from carbodiimides and reactive carbonates and an activating agent chosen from aminopyridines in an organic solvent chosen from ethers, ketones, esters, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between -10 and 90°C.

6. Process according to claim 4, characterized in that the esterification by means of the anhydride is carried out in the presence of an activating agent chosen from aminopyridines in an organic solvent chosen from ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between 0 and 90°C.

7. Process according to claim 4, characterized in that the esterification is carried out by means of a halide or an anhydride with an aliphatic or aromatic acid, optionally prepared in situ, the procedure being carried out in the presence of a base chosen from tertiary aliphatic amines in an organic solvent chosen from ethers, esters, ketones, nitriles,



aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between 0 and 80°C.

8. Process according to claim 4, characterized in that the acid treatment is carried out by means of an inorganic or organic acid in an organic solvent at a temperature of between -10 and 60°C.

9. Process according to claim 8, characterized in that the acid is chosen from hydrochloric, sulphuric, acetic, methanesulphonic, trifluoromethanesulphonic and p-toluenesulphonic acids, used alone or in the form of a mixture.

10. Process according to claim 8, characterized in that the solvent is chosen from alcohols, ethers, esters, halogenated aliphatic hydrocarbons, aromatic hydrocarbons and nitriles.

11. Process according to claim 4, characterized in that the replacement by a hydrogen atom of the protecting group G_1 representing a 2,2,2-trichloroethoxycarbonyl or 2-(2-trichloromethyl-propoxy)carbonyl radical is carried out by treatment using zinc, optionally combined with copper, in the presence of acetic acid at a temperature of between 30 and 60°C or by means of an inorganic or organic acid such as hydrochloric acid or acetic acid in solution in an aliphatic alcohol containing 1 to 3 carbon atoms or an aliphatic ester such as ethyl acetate, isopropyl acetate or n-butyl acetate in the presence of zinc





in which Ar and R_1 are defined as in one of claims 1, 2 or 3 and R_3 and R_4, which are identical or different, represent an alkyl radical containing 1 to 4 carbon atoms or an aralkyl radical whose alkyl portion contains 1 to 4 carbon atoms or an aryl radical, or alternatively R_3 represents a trihalomethyl radical or a phenyl radical substituted by a trihalomethyl radical

optionally combined with copper.

12. Process for the preparation of a product according to one of claims 1, 2 or 3, characterized in that a product of general formula:



in which G_1 represents a hydrogen atom or an acetyl radical or a hydroxy-protecting group, is esterified by means of an acid of general formula:



in which Ar and R_1 are defined as in one of claims 1, 2 or 3 and R_3 and R_4, which are identical or different, represent an alkyl radical containing 1 to 4 carbon atoms or an aralkyl radical whose alkyl portion contains 1 to 4 carbon atoms or an aryl radical, or alternatively R_3 represents a trihalomethyl radical or a phenyl radical substituted by a trihalomethyl radical and R_4 represents a hydrogen atom, or alternatively R_3 and R_4 form, together with the carbon atom to which they are attached, a 4- to 7-membered ring, to give a product of general formula:

and R_4 represents a hydrogen atom, or alternatively R_3 and R_4 form, together with the carbon atom to which they are attached, a 4- to 7-membered ring, to give, after treatment in acidic medium, a product of general formula:



in which Ar is defined as in one of claims 1, 2 or 3 and G_1 is defined as above, which is acylated by means of benzoyl chloride or a reactive derivative of general formula:

$$R_2\text{-O-CO-X}$$

in which R_2 is defined as in one of claims 1, 2 or 3 and X represents a halogen atom or a residue $-O-R_2$ or $-O-CO-O-R_2$, and then the protecting group G_1 is replaced, if necessary, by a hydrogen atom, and the product obtained is isolated.

13. Process according to claim 12, characterized in that the esterification is carried out by means of the free acid, the procedure being carried out in the presence of a condensing agent chosen from carbodiimides and reactive carbonates and an activating agent chosen from aminopyridines in an organic solvent chosen from ethers, ketones, esters, nitriles,



in which Ar is defined as in one of claims 1, 2 or 3 and G_1 is defined as above, which is acylated by means of benzoyl chloride or a reactive derivative of general formula:

$$R_2\text{-O-CO-X}$$

in which R_2 is defined as in one of claims 1, 2 or 3 and X represents a halogen atom or a residue $-O-R_2$ or $-O-CO-O-R_2$, and then the protecting group G_1 is replaced, if necessary, by a hydrogen atom, and the product obtained is isolated.

13. Process according to claim 12, characterized in that the esterification is carried out by means of the free acid, the procedure being carried out in the presence of a condensing agent chosen from carbodiimides and reactive carbonates and an activating agent chosen from aminopyridines in an organic solvent chosen from ethers, ketones, esters, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between -10 and 90°C.

14. Process according to claim 12, characterized in that the esterification by means of

aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between -10 and 90°C.

14. Process according to claim 12, characterized in that the esterification by means of the anhydride is carried out in the presence of an activating agent chosen from aminopyridines in an organic solvent chosen from ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between 0 and 90°C.

15. Process according to claim 12, characterized in that the esterification is carried out by means of a halide or an anhydride with an aliphatic or aromatic acid, optionally prepared in situ, the procedure being carried out in the presence of a base chosen from tertiary aliphatic amines in an organic solvent chosen from ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between 0 and 80°C.

16. Process according to claim 12, characterized in that the acid treatment is carried out by means of an inorganic or organic acid in an organic solvent at a temperature of between 0 and 50°C.

17. Process according to claim 16, characterized in that the acid is chosen from hydrochloric, sulphuric and formic acids.

the anhydride is carried out in the presence of an activating agent chosen from aminopyridines in an organic solvent chosen from ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between 0 and 90°C.

15. Process according to claim 12, characterized in that the esterification is carried out by means of a halide or an anhydride with an aliphatic or aromatic acid, optionally prepared in situ, the procedure being carried out in the presence of a base chosen from tertiary aliphatic amines in an organic solvent chosen from ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between 0 and 80°C.

16. Process according to claim 12, characterized in that the acid treatment is carried out by means of an inorganic or organic acid in an organic solvent at a temperature of between -10 and 60°C.

17. Process according to claim 16, characterized in that the acid is chosen from hydrochloric, sulphuric, hydrofluoric, formic, acetic, methanesuphonic, trifluoro-methanesulphonic and p-toluenesulphonic acids, used alone or in the form of a mixture.

18. Process according to claim 16, characterized in that the solvent is chosen from

18. Process according to claim 16, characterized in that the solvent is chosen from alcohols containing 1 to 3 carbon atoms.

19. Process according to claim 12, characterized in that the acylation is carried out in an inert organic solvent in the presence of an inorganic or organic base.

20. Process according to claim 19, characterized in that the inert organic solvent is chosen from esters and halogenated aliphatic hydrocarbons.

21. Process according to one of claims 18, 19 or 20, characterized in that the procedure is carried out at a temperature of between 0 and 50°C.



alcohols, ethers, esters, halogenated aliphatic hydrocarbons, aromatic hydrocarbons and nitriles.

19. Process according to claim 12, characterized in that the acylation is carried out in an inert organic solvent in the presence of an inorganic or organic base.

20. Process according to claim 19, characterized in that the inert organic solvent is chosen from esters and halogenated aliphatic hydrocarbons.

21. Process according to one of claims 18, 19 or 20, characterized in that the procedure is carried out at a temperature of between 0 and 50°C.

22. Process according to claim 12, characterized in that the replacement by a hydrogen atom of the protecting group G_1 representing a 2,2,2-trichloroethoxycarbonyl or 2-(2-trichloromethyl-propoxy)carbonyl radical is carried out by treatment using zinc, optionally combined with copper, in the presence of acetic acid at a temperature of between 30 and 60°C or by means of an inorganic or organic acid such as hydrochloric acid or acetic acid in solution in an aliphatic alcohol containing 1 to 3 carbon atoms or an aliphatic ester such as ethyl acetate, isopropyl acetate or n-butyl acetate in the presence of zinc optionally combined with copper.

23. Process for the preparation of a product according to one of claims 1, 2 or 3, characterized in


G1-O
O
R1-NH
O
Ar
O
O-G3
HO
H
O
OCOCH3
OCOC6H5

that a product of general formula:



in which G_1 represents a hydrogen atom or an acetyl radical or a hydroxy-protecting group, is esterified by means of an acid of general formula:



in which Ar and R_1 are defined as in one of claims 1, 2 or 3 and G_3 represents a hydroxy-protecting group, or of an activated derivative of this acid, to give a product of general formula:



in which Ar, R, R_1, G_1 and G_3 are defined as above, whose protecting groups G_3 and optionally G_1 are replaced by a hydrogen atom, and the product obtained is isolated.

24. Process according to claim 23,

in which Ar, R_1, G_1 and G_3 are defined as above, whose protecting groups G_3 and optionally G_1 are replaced by a hydrogen atom, and the product obtained is isolated.

24. Process according to claim 23, characterized in that the esterification is carried out by means of the free acid, the procedure being carried out in the presence of a condensing agent chosen from carbodiimides and reactive carbonates and an activating agent chosen from aminopyridines in an organic solvent chosen from ethers, ketones, esters, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between -10 and 90°C.

25. Process according to claim 23, characterized in that the esterification by means of the anhydride is carried out in the presence of an activating agent chosen from aminopyridines in an organic solvent chosen from ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between 0 and 90°C.

26. Process according to claim 23, characterized in that the esterification is carried out by means of a halide or an anhydride with an aliphatic or aromatic acid, optionally prepared in situ, the procedure being carried out in the presence of a base chosen from tertiary aliphatic amines in an organic solvent chosen from ethers, esters, ketones, nitriles,

characterized in that the esterification is carried out by means of the free acid, the procedure being carried out in the presence of a condensing agent chosen from carbodiimides and reactive carbonates and an activating agent chosen from aminopyridines in an organic solvent chosen from ethers, ketones, esters, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between -10 and 90°C.

25. Process according to claim 23, characterized in that the esterification by means of the anhydride is carried out in the presence of an activating agent chosen from aminopyridines in an organic solvent chosen from ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between 0 and 90°C.

26. Process according to claim 23, characterized in that the esterification is carried out by means of a halide or an anhydride with an aliphatic or aromatic acid, optionally prepared in situ, the procedure being carried out in the presence of a base chosen from tertiary aliphatic amines in an organic solvent chosen from ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between 0 and 80°C.

27. Process according to claim 23,

aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between 0 and 80°C.

27. Process according to claim 23, characterized in that the replacement of the protecting groups G_1 and G_3 by hydrogen atoms is carried out by treatment with zinc, optionally combined with copper, in the presence of acetic acid at a temperature of between 30 and 60°C or by means of an inorganic or organic acid such as hydrochloric acid or acetic acid in solution in an aliphatic alcohol containing 1 to 3 carbon atoms or an aliphatic ester such as ethyl acetate, isopropyl acetate or n-butyl acetate in the presence of zinc optionally combined with copper, when G_1 and G_3 represent a 2,2,2-trichloroethoxycarbonyl or 2-(2-trichloromethylpropoxy)carbonyl radical, or by treatment in acidic medium such as for example hydrochloric acid in solution in an aliphatic alcohol containing 1 to 3 carbon atoms (methanol, ethanol, propanol or isopropanol) or aqueous hydrofluoric acid at a temperature of between 0 and 40°C when G_3 represents silylated radical or an acetal residue, followed by the replacement of the protecting group G_1 by treatment using zinc, optionally combined with copper, in the presence of acetic acid at a temperature of between 30 and 60°C or by means of an inorganic or organic acid such as hydrochloric acid or acetic acid in solution in an aliphatic alcohol containing 1 to 3

characterized in that the replacement of the protecting groups G_1 and G_3 by hydrogen atoms is carried out by treatment with zinc, optionally combined with copper, in the presence of acetic acid at a temperature of between 30 and 60°C or by means of an inorganic or organic acid such as hydrochloric acid or acetic acid in solution in an aliphatic alcohol containing 1 to 3 carbon atoms or an aliphatic ester such as ethyl acetate, isopropyl acetate or n-butyl acetate in the presence of zinc optionally combined with copper, when G_1 and G_3 represent a 2,2,2-trichloroethoxycarbonyl or 2-(2-trichloromethylpropoxy)carbonyl radical, or by treatment in acidic medium such as for example hydrochloric acid in solution in an aliphatic alcohol containing 1 to 3 carbon atoms (methanol, ethanol, propanol or isopropanol) or aqueous hydrofluoric acid at a temperature of between 0 and 40°C when G_3 represents an acetal residue, followed by the replacement of the protecting group G_1 by treatment using zinc, optionally combined with copper, in the presence of acetic acid at a temperature of between 30 and 60°C or by means of an inorganic or organic acid such as hydrochloric acid or acetic acid in solution in an aliphatic alcohol containing 1 to 3 carbon atoms or an aliphatic ester such as ethyl acetate, isopropyl acetate or n-butyl acetate in the presence of zinc optionally combined with copper.

28. Process according to claim 23,

carbon atoms or an aliphatic ester such as ethyl acetate, isopropyl acetate or n-butyl acetate in the presence of zinc optionally combined with copper.

28. Process according to claim 23, characterized in that when G_3 represents a radical $-CH_2-Ph$, the replacement of the group by a hydrogen atom is carried out by hydrogenolysis, after replacing the protecting group G_1 under the conditions of claim 27.

29. New taxoid of general formula:



in which G_1 represents a hydrogen atom or an acetyl radical or a hydroxy-protecting group.

characterized in that when G_3 represents a radical $-CH_2-Ph$, the replacement of the group by a hydrogen atom is carried out by hydrogenolysis, after replacing the protecting group G_1 under the conditions of claim 27.

29. New taxoid of general formula:



in which G_1 represents a hydrogen atom or an acetyl radical or a hydroxy-protecting group.

30. Pharmaceutical composition characterized in that it contains at least one product according to one of claims 1, 2 or 3, in combination with one or more pharmaceutically acceptable products, whether inert or physiologically active.

DOCUMENT CONTAINING CORRECTIONS

(FRENCH) PAGE(S) OF THE DESCRIPTION OR OF THE CLAIMS OR SHEET(S) OF DRAWINGS			* R.M.	DATE OF THE CORRESPONDENCE	DATE STAMP OF THE CORRECTOR
Amended	Omitted	Added			
3,15,24, 26				15 March 93	19 APR. 1993 LA
27,29,30, 32,33				15 March 93	19 APR. 1993 LA

* A change made in the wording of the original claims, unless the change derives from the provisions of Article 28 of the decree of 19th September 1979, is indicated by the reference "R.M." (amended claims).

BT 244/171180